Summary of Natera's Conference Call Company Overview - Natera is a diagnostics and life science tools company, focusing on genetic testing and monitoring, particularly in oncology and women's health [1] Financial Performance - Q4 results showed strong revenue growth, with record volumes for Signatera, a product for minimal residual disease (MRD) monitoring [2][3] - Gross margins reached approximately 67%, with a sequential increase of 240 basis points from Q3 [3] - The company generated over $100 million in free cash flow for the year, indicating strong financial health [9] - Natera aims for continued revenue growth across its portfolio, particularly in women's health and organ health, with a focus on pricing improvements for Signatera [11] Product Development and Market Strategy - Natera is expanding Signatera's penetration among oncologists, with 50% of oncologists currently ordering the test [14] - The company sees significant opportunities for growth in both indication expansion and deeper adoption within existing practices [15][16] - Natera is committed to aggressive R&D spending to support clinical trials and new product development, maintaining a stable SG&A year-on-year [12] Coverage and Reimbursement - Approximately 30%-35% of Signatera's volume comes from non-covered areas, representing a potential $200 million opportunity if coverage expands [20] - Natera is actively working with Medicare to improve coverage for various cancer types, with expectations for more announcements in the near future [24][25] - The company has improved its reimbursement rates from Medicare Advantage plans, currently at 80% compared to 99% for Medicare fee-for-service [27] Clinical Guidelines and Adoption - Clinical guidelines remain crucial for the adoption of Signatera, with ongoing studies expected to support guideline inclusion for colorectal cancer and muscle-invasive bladder cancer [30][31] - Natera is optimistic about the potential for guideline updates that could enhance the adoption of Signatera in clinical practice [32][33] Women's Health Segment - Natera's women's health business is projected to grow mid-single digits, driven by increased interest in carrier screening and ongoing product innovation [53][54] - The recent launch of the Fetal Focus test is part of Natera's strategy to maintain competitiveness in a challenging market [56] R&D and Future Outlook - Natera is focused on growing its R&D investments to drive innovation and improve product offerings, with a bias towards ambitious clinical trials [71] - The company aims to achieve sustainable earnings per share through revenue growth and efficient operational management [66] Conclusion - Natera is well-positioned for future growth with a strong product pipeline, ongoing improvements in reimbursement, and a commitment to innovation in both oncology and women's health [73]

Financial Data and Key Metrics Changes - The company processed approximately 924,000 tests in Q4 2025, achieving a record growth of 56% in MRD clinical unit tests compared to Q4 2024 [6][10] - Revenue for the quarter reached around $666 million, representing a 40% increase year-over-year [6][7] - Gross margin improved to 66.9% in Q4, exceeding expectations and reflecting strong operational performance [6][11] - Cash flow generated in 2025 was over $107 million, with expectations for continued strong cash flow in 2026 [7][30] Business Line Data and Key Metrics Changes - The MRD product portfolio expanded significantly with the launch of the genome version of Signatera and the Latitude MRD test, contributing to strong growth in oncology [8][9] - The average selling price (ASP) for Signatera increased to approximately $1,225 in Q4, with cash collections accelerating [11][30] - The women's health segment saw robust performance, particularly with the Fetal Focus test, which achieved high sensitivity and specificity [15][16] Market Data and Key Metrics Changes - Over 50% of oncologists in the U.S. ordered a Signatera test in Q4, indicating strong adoption of MRD testing in clinical practice [10] - The company is seeing increased engagement from commercial payers, enhancing reimbursement opportunities for its tests [12][30] Company Strategy and Development Direction - The company plans to generate between $2.62 billion and $2.7 billion in revenues for 2026, with a focus on maintaining gross margins between 63% and 65% while investing in R&D [7][31] - Strategic investments in clinical trials and product launches are expected to drive future growth, particularly in oncology and women's health [8][36] - The company is pursuing broader Medicare reimbursement for Signatera, which could significantly enhance revenue potential [12][30] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth trajectory, citing strong performance in Q4 and a solid start to 2026 [6][7] - The company is focused on maintaining operational improvements and expects to continue narrowing operating losses while investing in growth [30][31] - Management highlighted the importance of generating clinical evidence to support product adoption and reimbursement [46][61] Other Important Information - The company completed the acquisition of Foresight Diagnostics, integrating phased variant technology to enhance MRD test sensitivity [27][28] - The Latitude MRD assay has shown promising clinical validation, with significant prognostic capabilities for colorectal cancer [24][25] Q&A Session Summary Question: Update on Signatera ASPs and Medicare changes - Management indicated that changes in ADLT rates and bundle rates roughly net each other out, with continued execution on reimbursement expected to drive ASP growth [38][39] Question: Signatera mix by indication and potential impact on ASPs - The majority of Signatera volume comes from CRC, but management anticipates that breast and lung cancer indications will gain traction, potentially impacting ASPs positively [41][42] Question: Growth expectations for Signatera and data catalysts - Management suggested using trailing four-quarter averages for modeling growth, with expectations for continued strong performance across various tumor types [45][50] Question: Marketing approach for Fetal Focus and market share - Management noted significant physician interest in Fetal Focus, with flexible ordering options contributing to market share gains [52][54] Question: Contribution from lymphoma and multiple myeloma volumes - Management acknowledged limited current contributions from these areas but sees potential for growth driven by the Foresight team and their data [74][75] Question: Approval and launch plans for Signatera in Japan - Management confirmed a strong sales team and distribution partnership in Japan, anticipating a positive impact on revenue once approval is secured [76][79]

Financial Data and Key Metrics Changes - The company generated approximately $666 million in revenue for Q4 2025, representing a 40% increase compared to Q4 2024 [6][30] - Gross margin for the quarter was 66.9%, exceeding expectations and reflecting a significant improvement [6][11] - Cash flow for the year reached over $107 million, indicating strong financial health despite increased growth investments [7][30] Business Line Data and Key Metrics Changes - The company processed about 924,000 tests in Q4 2025, with MRD clinical unit growth reaching 225,000 tests, a 56% increase year-over-year [6][10] - Average selling prices (ASPs) for Signatera increased to approximately $1,225 in Q4 2025, contributing to revenue growth [11][30] - The Women's Health segment saw significant growth, particularly with the launch of the Fetal Focus test, which is expected to drive further market share gains [15][54] Market Data and Key Metrics Changes - Over 50% of oncologists in the U.S. ordered a Signatera test in Q4 2025, indicating strong adoption of MRD testing in clinical practice [10] - The company anticipates continued growth in Women's Health volumes and ASPs, with a strong start to 2026 [33][64] - The Organ Health products are expected to maintain a growth trajectory, driven by the increasing relevance of cell-free DNA in patient care [64] Company Strategy and Development Direction - The company plans to generate between $2.62 billion and $2.7 billion in revenues for 2026, with a focus on maintaining gross margins between 63% and 65% [7][31] - Investments will continue in R&D and clinical trials, particularly in MRD and early cancer detection technologies [36] - The company is pursuing broader Medicare reimbursement for Signatera, which could enhance ASPs and revenue potential [12][30] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's growth trajectory, citing strong performance in Q4 2025 and a solid start to 2026 [6][7] - The management highlighted the importance of clinical data generation and its role in expanding market share across various cancer types [20][61] - There is a clear path to profitability, with a focus on balancing growth investments and operational efficiency [30][36] Other Important Information - The company has submitted its Latitude tissue-free MRD assay to MolDX, which is expected to enhance its product offerings in colorectal cancer [24][26] - The acquisition of Foresight Diagnostics is anticipated to strengthen the company's capabilities in MRD testing [27][30] Q&A Session Summary Question: Can you discuss the net ASP impact from changes in Medicare rates? - Management indicated that changes in ADLT rates and bundle rates roughly net each other out, with continued execution on reimbursement expected to drive ASP growth [38] Question: What is the current mix of Signatera by indication? - The majority of Signatera volume is currently from colorectal cancer, but other tumor types are beginning to accelerate, with a significant focus on expanding coverage for additional indications [41][68] Question: How does the company view the potential for growth in heme MRD volumes? - Management acknowledged that while the current contribution from heme MRD volumes is limited, there is significant upside potential as the company leverages its recent acquisition and data generation capabilities [74] Question: What are the expectations for the Women's Health market in 2026? - The company expects to see mid-single-digit growth in Women's Health volumes, with potential for revenue growth driven by pricing gains [64]

Financial Data and Key Metrics Changes - The company processed approximately 924,000 tests in Q4 2025, with MRD clinical unit growth reaching 225,000 tests, a 56% increase compared to Q4 2024 [5][10] - Revenue for the quarter was around $666 million, representing a 40% growth year-over-year [5][6] - Gross margin for Q4 was reported at 66.9%, exceeding expectations and reflecting strong operational performance [5][11] - Cash flow generated in 2025 was over $107 million, with expectations for continued strong cash flow in 2026 [6][29] Business Line Data and Key Metrics Changes - The MRD product portfolio was significantly expanded with the launch of the genome version of Signatera and the Latitude MRD test [9][25] - The Fetal Focus single gene NIPT test was launched, addressing unmet clinical needs and showing robust performance metrics [12][14] - The organ health portfolio, particularly the Prospera donor DNA monitoring, continues to evolve, with significant investments aimed at improving clinical utility [16][18] Market Data and Key Metrics Changes - Over 50% of oncologists in the U.S. ordered a Signatera test in Q4, indicating strong adoption of MRD testing in clinical practice [10] - The company anticipates continued growth in women's health volumes and ASPs, with a strong start in Q1 2026 [32][62] - The organ health products are expected to maintain a growth trend, driven by the increasing relevance of cell-free DNA in patient care [62] Company Strategy and Development Direction - The company plans to invest in R&D while holding SG&A stable, focusing on targeted investments to drive future growth [6][36] - There is a strong emphasis on expanding reimbursement coverage for Signatera, with ongoing efforts to secure broader Medicare reimbursement [12][30] - The integration of AI-enabled workflows is expected to enhance operational efficiency and reimbursement processes [12][30] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the operational and financial outlook for 2026, expecting revenue between $2.62 billion and $2.7 billion [6][30] - The company is focused on maintaining a path to profitability while continuing to invest in growth opportunities [29][36] - Management highlighted the importance of generating clinical evidence to support product adoption and market expansion [19][46] Other Important Information - The company has submitted its Latitude MRD assay to MolDX for colorectal cancer, which is expected to enhance MRD assessment capabilities [24][25] - The phased variant technology integrated into the Signatera platform is anticipated to improve detection sensitivity significantly [25][26] Q&A Session Summary Question: Can you discuss the net ASP impact from changes in Medicare rates? - Management indicated that changes in ADLT rates and bundle rates roughly net each other out, with continued execution on reimbursement for covered services expected to drive ASP growth [38] Question: What is the current mix of Signatera by indication? - The majority of Signatera volume is currently from CRC, but management expects other tumor types like breast and lung to gain traction, potentially normalizing the mix over time [66] Question: What are the expectations for women's health market share in 2025? - The company reported a record year in women's health and anticipates further growth with the introduction of the Fetal Focus test, which is expected to attract new customers [82]

Natera, Inc. Q4'2025 Earnings Presentation February 26, 2026 Safe harbor statement This presentation contains forward-looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our market opportunity, our anticipated products and launch schedules, our reimbursement coverage and our product costs, our commercial and strategic partnerships and potential acq ...

Core Insights - The 2026 CES showcased AI PCs as the main focus, highlighting a shift towards integrating AI into consumer electronics [1][3] - Major brands like Samsung, Dell, HP, Lenovo, and Asus presented AI PCs, setting a developmental tone for the industry [3] Consumer Market - AI PCs are marketed as future-proof devices, meeting consumer demand for longevity and practicality [4] - Microsoft's Surface Laptop 7 exemplifies advanced AI capabilities, enhancing user experience in image processing and video editing [4] - The introduction of affordable AI laptops is anticipated as technology costs decrease [6] Enterprise Solutions - AI PCs offer significant advantages for enterprise clients, with features like real-time security monitoring and automated IT management [6] - AI capabilities improve efficiency in document handling and facilitate global collaboration through real-time translation [6] Software Advancements - Software experience is crucial for AI PC dominance, with Microsoft expanding its Copilot Plus PC ecosystem [7] - Features like real-time translation and context-aware search enhance user interaction and productivity [7][9] Hardware Innovations - The success of AI PCs at CES is attributed to the maturity of dedicated AI hardware, including processors with neural network processing units (NPU) [10] - Intel's Core Ultra Series 3 platform and Qualcomm's Snapdragon processors demonstrate significant performance improvements and energy efficiency [12] Market Positioning - AI branding is now present across various laptop segments, not limited to flagship models, promoting wider adoption of AI PCs [13]

Summary of Natera's Conference Call Company Overview - **Company**: Natera - **Industry**: Life Sciences, Diagnostics, Oncology, Women's Health - **Core Mission**: Transforming disease management globally through proprietary technology that detects small quantities of DNA [2][3] Key Products and Market Position - **Panorama**: A cell-free fetal DNA test for chromosomal abnormalities, leading with over 50% market share [2] - **Prospera**: A test for organ transplant rejection using donor-derived cell-free DNA [2] - **Signatera**: A circulating tumor DNA test for minimal residual disease (MRD) monitoring, achieving record growth with 22,000 clinical MRD tests in Q4 [3][4] Financial Performance - **Q4 2025 Revenue**: $660 million, up 39% year-over-year, driven by strong average selling prices (ASPs) and volume growth [4] - **Free Cash Flow**: Exceeded $100 million for the year [5] - **Unit Sales**: 924,000 units in Q4, with significant growth in oncology and women's health [3][4] Innovations and Future Growth Drivers - **Fetal Focus**: A new 21-gene single-gene NIPT test aimed at severe genetic disorders, filling a gap in clinical care [5][6] - **Signatera Enhancements**: Incorporation of phased variants technology for improved sensitivity, targeting a limit of detection (LOD) down to one part per 10 million [10][11] - **AI Integration**: Development of an augmented MRD score using AI and a foundation model to enhance precision in risk assessment [12][13] Clinical Trials and Partnerships - **Clinical Trials**: Significant investments in clinical trials, particularly in breast cancer, with over $100 million allocated for evidence generation [16][17] - **STELLAR Trial**: A pivotal phase three trial in colorectal cancer, leveraging Signatera for patient enrollment [18][35] - **Partnerships**: Collaborations with NVIDIA for AI initiatives and Ultima Genomics for new product launches [22] Market Dynamics and Competitive Landscape - **Market Share**: Natera holds over 50% market share in women's health and is focused on maintaining and expanding its position through innovation and clinical evidence [25][39] - **Lymphoma Market**: Interest in expanding into lymphoma and hematologic cancers, leveraging Foresight Diagnostics' technology [27][28] Regulatory and Reimbursement Strategies - **Medicare Coverage**: Ongoing efforts to expand Multi-X coverage, with 30% of tests currently not covered under Medicare [21] - **Reimbursement Process**: Coordination with MolDX for new assay coverage, emphasizing the importance of generating data [32] Future Outlook - **2026 Goals**: Plans to complete enrollment for the FIND study in early cancer detection and launch new products incorporating advanced technologies [21][22] - **Operating Margins**: Expectation of growing into profitability as revenue matures, with a focus on maintaining operational efficiency [46][48] Conclusion Natera is positioned for significant growth through innovative product offerings, strategic partnerships, and a strong focus on clinical evidence generation. The company aims to leverage its market leadership in diagnostics to expand into new therapeutic areas while enhancing its existing product lines.

Natera, Inc. Investor presentation J.P. Morgan Healthcare Conference January 13, 2026 1 Safe harbor statement This presentation containsforward-looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. Allstatements other than statements of historical facts contained in this presentation, including statements regarding our market opportunity, our anticipated products and launch schedules, our reimbursement coverage and our product costs, our commercial and strategic partn ...

Natera FY Conference Summary Company Overview - Natera is a leading diagnostic company specializing in cell-free DNA technology, particularly in prenatal testing and minimal residual disease (MRD) testing [3][5] Financial Performance - Q3 results showed a revenue beat of $25 million, leading to an increase in full-year guidance by $160 million, tracking towards 30% growth on a multibillion-dollar base [7][12] - The women's health business has seen outstanding revenue growth due to improved insurance coverage for tests [12] Product Insights - **Signatera**: - The product is becoming a standard in cancer care, with significant adoption among oncologists and patients [8][9] - Long-term growth target for Signatera is projected at $5 billion in annual sales with gross margins approaching 70% [13] - Current revenue in oncology is expected to be around $1 billion, with potential for significant growth [15][16] - **Market Penetration**: - Colorectal cancer represents a significant opportunity, with an estimated annual testing volume of 1.25 million tests in the U.S. [20][22] - Current utilization is low, with only 400,000 units run-rated against the potential market [23] - **International Expansion**: - Plans to launch in Japan in 2027, which could double the annual volume opportunity [24][26] Competitive Landscape - Natera does not claim to own the market but acknowledges the presence of many companies working on similar problems [29] - The company is focused on maintaining a competitive edge through innovation and addressing significant clinical needs [62] Reimbursement and Regulatory Developments - Natera is actively working on MolDX submissions to improve Medicare coverage, which currently affects about 30% of their volume [38][40] - The company is seeing positive effects from biomarker bills in various states, which could enhance reimbursement opportunities [40][42] Future Outlook - Natera is optimistic about achieving cash flow break-even by mid-2024 and expects to generate sustainable cash flow thereafter [18] - The company is committed to investing in R&D and clinical trials to support its growth strategy, particularly in early cancer detection [17][54] Key Challenges - The company faces challenges in ensuring coverage and reimbursement for its tests, particularly in navigating the complexities of Medicare and commercial payers [46][48] - There is a need to balance operational expenditures with growth opportunities while maintaining high-quality R&D [17][19] Conclusion - Natera is positioned for significant growth in the diagnostic space, particularly with its innovative products like Signatera and its expansion into new markets. The company is focused on solving critical healthcare problems while navigating the complexities of reimbursement and competition in the industry [60][64]

Financial Data and Key Metrics Changes - The company generated $592 million in revenue for Q3 2025, representing a 35% increase compared to Q3 2024 [6][14] - Gross margins improved to 64.9%, nearly 1.5 percentage points higher than the previous quarter and almost 3 percentage points higher than Q3 of last year [7][15] - The company raised its revenue guidance for 2025 by $160 million, now expecting revenues between $2.18 billion and $2.26 billion [8][41] - Free cash flow generation guidance was increased to approximately $100 million for the full year [10][41] Business Line Data and Key Metrics Changes - The company processed 202,000 clinical MRD tests in Q3, with a growth of over 21,500 units compared to Q2 [7][12] - Signatera ASPs reached approximately $1,200, with significant growth in cash collections and a record for days sales outstanding (DSOs) at 49 days [14][15] - Women's health and organ health segments showed strong performance, contributing to overall revenue growth [11][14] Market Data and Key Metrics Changes - The company reported a 56% year-on-year growth in clinical MRD unit growth, marking the fastest growth rate in 2023 [12] - The adoption of Signatera is being fueled by positive clinical data and strong customer experiences, with a broad mix of tumor types being treated [13][30] Company Strategy and Development Direction - The company plans to submit seven new MolDX submissions by the end of the year, potentially worth $250 million to $300 million in gross profit [9][18] - Investments are being made to expand the market through clinical trials and to support FDA-enabling studies for early cancer detection [10][19] - The company aims to maintain limited OPEX growth of around 10% while revenues are expected to grow significantly faster [19][45] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the momentum in revenue and volume growth, particularly in oncology and women's health [6][10] - The company anticipates that the recent clinical data will enhance adoption rates for Signatera among oncologists [26][30] - Management highlighted the importance of ongoing investments in R&D and clinical trials to sustain growth and innovation [17][19] Other Important Information - The Fetal Focus product was expanded to cover over 20 genes, with positive initial feedback from the medical community [11][22] - The company is leveraging AI to enhance operational efficiency and scale without a proportional increase in headcount [16][19] Q&A Session Summary Question: Why is now the right time for the new Fetal Focus test? - The five-gene panel received great feedback, and R&D is ready to launch the broader panel as part of the plan [48] Question: How is the path to NCC guidelines being shaped by recent clinical utility data? - The InVigor 011 data is expected to be included in NCCN guidelines, with updates anticipated mid to late next year [54] Question: How important was the PRECEDE-CRC advanced adenoma performance in shaping investment decisions? - The performance achieved influenced the decision to invest further in the program, with strong results prompting the initiation of the FIND study [58][60] Question: Can you provide insights on the contribution from new patient starts for Signatera? - New patient starts in Q3 were at record levels, similar to Q2, indicating strong ongoing interest and adoption [85]